3-溴-4-乙氧基苯甲酸 | 24507-29-7

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-4-乙氧基苯甲酸
• 英文名称: 3-Bromo-4-ethoxybenzoic Acid
• 英文别名: 4-ethoxy-3-bromo-benzoic acid；4-Aethoxy-3-brom-benzoesaeure；3-bromo-4-ethoxy-benzoic acid
• CAS: 24507-29-7
• 化学式: C₉H₉BrO₃
• mdl: MFCD01143606
• 分子量: 245.073
• InChiKey: XCKMWULLKHQZIP-UHFFFAOYSA-N

物化性质

• 沸点：
  337.2±27.0 °C(Predicted)
• 密度：
  1.544±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  3-溴-4-乙氧基苯甲酸 在 吡啶 、 chromium(VI) oxide 、 氯化亚砜 作用下， 以 溶剂黄146 为溶剂， 生成
  参考文献：
  名称：

  Schaefer, W.; Uhlig, G.; Zaschke, H., Molecular Crystals and Liquid Crystals (1969-1991), 1990, vol. 191, p. 269 - 276

  摘要：

  DOI：
• 作为产物：
  描述：

  2-溴-1-乙氧基-4-甲苯 在 potassium permanganate 作用下， 生成 3-溴-4-乙氧基苯甲酸
  参考文献：
  名称：

  Bogert; Hamann, American perfumer, 1930, vol. 25, p. 19,75

  摘要：

  DOI：

文献信息

• Aromatic amine derivative and use thereof
  申请人：Taniguchi Takahiko

  公开号：US20090325956A1

  公开（公告）日：2009-12-31

  The present invention provides a novel SCD inhibitor. An SCD inhibitor containing a compound represented by the formula [I] wherein ring A is an optionally substituted aromatic ring, ring B is an optionally substituted ring, ring C is an optionally substituted aromatic ring, R is a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, and X is a spacer having 1 to 5 atoms in the main chain, or a salt thereof, or a prodrug thereof.

  本发明提供了一种新型SCD抑制剂。一种包含由下式[I]表示的化合物的SCD抑制剂 其中环A是可选择取代的芳香环，环B是可选择取代的环，环C是可选择取代的芳香环，R是氢原子，可选择取代的碳氢基团或可选择取代的杂环基团，X是具有主链中1到5个原子的间隔物，或其盐，或其前药。
• [EN] ARYL-1,3-AZOLE DERIVATIVES AND METHODS FOR INHIBITING HEPARNASE ACTIVITY<br/>[FR] DERIVES D'ARYL-1,3-AZOLE ET PROCEDES PERMETTANT D'INHIBER L'ACTIVITE DE L'HEPARANASE
  申请人：IMCLONE SYSTEMS INC

  公开号：WO2005030206A1

  公开（公告）日：2005-04-07

  The present invention encompasses heparanase inhibitors, particularly to certain 2-substituted heteroaryl-fused and aryl-fused carbazole derivatives that inhibit heparanase, pharmaceutical compositions that contain the compounds, methods for making the compounds, and methods of treating heparanase-dependent diseases and conditions in mammals by administering a therapeutically effective amount of the compounds to the mammals.

  本发明涵盖了抑制肝素酶的抑制剂，特别是特定的2-取代杂芳基融合和芳基融合的咔唑衍生物，这些衍生物抑制肝素酶，包含这些化合物的药物组合物，制备这些化合物的方法，以及通过向哺乳动物施用这些化合物的治疗有效量来治疗依赖肝素酶的疾病和病况的方法。
• Substituted isoquinoline derivatives and their use as anticonvulsants
  申请人：SmithKline Beecham p.l.c.

  公开号：US20010025045A1

  公开（公告）日：2001-09-27

  This invention relates to substituted isoquinoline derivatives and their use as anticonvulsants.

  这项发明涉及替代异喹啉衍生物及其作为抗癫痫药物的用途。
• Novel compounds
  申请人：SmithKline Beecham p.l.c.

  公开号：US20030036551A1

  公开（公告）日：2003-02-20

  1 Compounds of formula (I) wherein Q is a monocyclic or bicyclic aryl or heteroaryl ring; R 1 is hydrogen; R 2 is hydrogen or up to three substituents selected from halogen, NO 2 , CN, N 3 , CF 3 O—, CF 3 S—, CF 3 SO 2 —, CF 3 CO—, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 perfluoroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, C 1-6 alkylO—C 1-6 alkylCO—, C 3-6 cycloalkylO—, C 3-6 cycloalkylCO—, C 3-6 cycloalkyl-C 1-4 alkylO—, C 3-6 cycloalkyl-C 1-4 alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 alkyl-, C 1-6 alkylS—, C 1-6 alkylSO 2 —, (C 1-4 alkyl) 2 NSO 2 —,(C 1-4 alkyl)NHSO 2 —, (C 1-4 alkyl) 2 NCO—, (C 1-4 alkyl)NCHO—, or CONH 2 , or —NR 3 R 4 where R 3 is hydrogen or C 1-4 alkyl, and R 4 is hydrogen, C 1-4 alkyl, formyl, —CO 2 C 1-4 alkyl, or —COC 1-4 alkyl, or two R 2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; X is halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl, and; Y is hydrogen, halogen, C 1-6 alkoxy, C 1-6 alkyl, or C 1-6 perfluoroalkyl; but excluding the compounds N-(5-Iodo-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-azidobenzamide and N-(5-iodo-1,2,3,4-tetrahydroiso-quinolin-7-yl)-5-benzoyl-2-methoxybenzamide; and pharmaceutically acceptable salts or solvates thereof possess anticonvulsant activity and are useful in the treatment of a variety of disorders.

  化合物的公式为（I），其中Q是单环或双环芳基或杂环芳基环；R1为氢；R2为氢或最多三个取自卤素、NO2、CN、N3、CF3O-、CF3S-、CF3SO2-、CF3CO-、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基-、C1-6烷基O-C1-6烷基CO-、C3-6环烷基O-、C3-6环烷基CO-、C3-6环烷基-C1-4烷基O-、C3-6环烷基-C1-4烷基CO-、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基-、C1-6烷基S-、C1-6烷基SO2-、（C1-4烷基）2NSO2-、（C1-4烷基）NHSO2-、（C1-4烷基）2NCO-、（C1-4烷基）NCHO-或CONH2，或—NR3R4，其中R3为氢或C1-4烷基，R4为氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基，或两个R2基组成一个饱和或不饱和的碳环，未取代或被—OH或═O取代；X为卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；Y为氢、卤素、C1-6烷氧基、C1-6烷基或C1-6全氟烷基；但不包括N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-4-叠氮苯甲酰胺和N-(5-碘-1,2,3,4-四氢异喹啉-7-基)-5-苯甲酰基-2-甲氧基苯甲酰胺；其药学上可接受的盐或溶剂化合物具有抗癫痫活性，并可用于治疗多种疾病。
• Tetrahydronaphthyridinyl-carboxamides having anti-convulsant activity
  申请人：SmithKline Beecham p.l.c.

  公开号：US20020143029A1

  公开（公告）日：2002-10-03

  Compounds of formula (I) and pharmaceutically acceptable salts and solvates: 1 where R 1 is hydrogen, C 1-6 alkyl (optionally substituted by hydroxy or C 1-4 alkoxy), phenyl-C 1-4 alkyl-, C 1-6 alkenyl, C 1-6 alkynyl; R 2 is hydrogen or up to three substituents selected from halogen, NO 2 , CN, N 3 , CF 3 O—, CF 3 S—, CF 3 CO—, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 perfluoroalkyl, C 3-6 cycloalkyl, C 3-6 cycloalkyl-C 1-4 alkyl-, C 1-6 alkylO—, C 1-6 alkylCO—, C 3-6 cycloalkylO—, C 3-6 cycloalkylCO—, C 3-6 cycloalkyl-C 1-4 alkylO—, C 3-6 cycloalkyl-C 1-4 alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4 alkyl-, C 1-6 alkylS—, C 1-6 alkylSO 2 —, (C 1-4 alkyl) 2 NSO 2 —, (C 1-4 alkyl)NHSO 2 —, (C 1-4 alkyl) 2 NCO—, (C 1-4 alkyl)NHCO— or CONH 2 ; or —NR 5 R 6 where R 5 is hydrogen or C 1-4 alkyl, and R 6 is hydrogen, C 1-4 alkyl, formyl, —CO 2 C 1-4 alkyl or —COC 1-4 alkyl; or two R 2 groups together form a carbocyclic ring that is saturated or unsaturated. R 3 groups and R 4 groups are each independently hydrogen or C 1-6 alkyl and/or the two R 3 groups and/or the two R 4 groups together form a C 3-6 spiroalkyl group, provided that at least one R 3 or R 4 group is not hydrogen; and X is selected from hydrogen, halogen, cyano, alkyl and alkoxy. are useful in the treatment and prophylaxis of epilepsy, migraine, and other disorders.

  公式（I）化合物及其药学上可接受的盐和溶剂化合物：其中R1为氢、C1-6烷基（可选地被羟基或C1-4烷氧基取代）、苯基-C1-4烷基、C1-6烯基、C1-6炔基；R2为氢或最多三个取代基，所选自卤素、NO2、CN、N3、CF3O—、CF3S—、CF3CO—、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷氧基、C1-6烷基CO—、C3-6环烷基烷氧基、C3-6环烷基CO—、C3-6环烷基-C1-4烷氧基、C3-6环烷基-C1-4烷基CO—、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基S—、C1-6烷基SO2—、（C1-4烷基）2NSO2—、（C1-4烷基）NHSO2—、（C1-4烷基）2NCO—、（C1-4烷基）NHCO—或CONH2；或—NR5R6，其中R5为氢或C1-4烷基，R6为氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基；或两个R2基共同形成一个饱和或不饱和的碳环。R3基和R4基各自独立地为氢或C1-6烷基，或两个R3基和/或两个R4基共同形成一个C3-6螺环烷基，前提是至少有一个R3或R4基不是氢；X选自氢、卤素、氰基、烷基和烷氧基。这些化合物对于治疗和预防癫痫、偏头痛和其他疾病是有用的。